Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12341227 | 0.81 | GRIN2D (0.35) | MAOAMAOB | |
| SCHEMBL13488628 | 0.79 | EPHX1 (0.47) | — | |
| SCHEMBL10566374 | 0.77 | KDM1A (0.34) | KDM1AMAOAMAOB | |
| SCHEMBL19161737 | 0.77 | KDM1A (0.62) | KDM1A | |
| SCHEMBL25983407 | 0.77 | KDM1A (0.42) | KDM1A | |
| SCHEMBL21473435 | 0.77 | KDM1A (0.37) | KDM1A | |
| Hydrochloric Acid SCHEMBL10755392 | 0.75 | MMP1 (0.35) | KDM1A | |
| SCHEMBL13046403 | 0.74 | MAOA (0.36) | MAOAMAOBTDP1 | |
| SCHEMBL23419210 | 0.73 | KDM1A (0.37) | KDM1A | |
| SCHEMBL19167980 | 0.72 | KDM1A (0.39) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324257-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIF18B | KDM1A 580/4885MAOA 3651/4885MAOB 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.